Biovie is trading 6.04% down at $2.01 after closing at $2.14 on August 24, 2026; the immediate catalyst remains unclear.

  • No verified company-specific announcement dated August 24 was identified.
  • Recent coverage points to previously released Parkinson’s trial results and an August 14 securities-registration filing, neither of which directly explains the decline.
  • The move follows an unusually volatile rebound, while broader indices were only modestly mixed.